Search Results - "Maples, P B"

  • Showing 1 - 20 results of 20
Refine Results
  1. 1

    Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients by Nemunaitis, J, Nemunaitis, M, Senzer, N, Snitz, P, Bedell, C, Kumar, P, Pappen, B, Maples, P B, Shawler, D, Fakhrai, H

    Published in Cancer gene therapy (01-08-2009)
    “…In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response…”
    Get full text
    Journal Article
  2. 2

    Cellular immune profile of patients with advanced cancer before and after taxane treatment by TONG, A. W, SEAMOUR, B, LAWSON, J. M, ORDONEZ, G, VUKELJA, S, HYMAN, W, RICHARDS, D, STEIN, L, MAPLES, P. B, NEMUNAITIS, J

    Published in American journal of clinical oncology (01-10-2000)
    “…The purpose of this study is to determine immune recovery and function after treatment with docetaxel or paclitaxel. Peripheral blood mononuclear cells were…”
    Get full text
    Journal Article
  3. 3

    Immune response and survival of refractory cancer patients who received TGF- beta 2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine by Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

    Published in Gene therapy (01-09-2013)
    “…TAG vaccine is a novel 'triad vaccine' that involves transfection of autologous tumor with a dual plasmid, TGF beta 2 antisense gene and GM-CSF gene. Patients…”
    Get full text
    Journal Article
  4. 4

    Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine by Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

    Published in Gene therapy (01-09-2013)
    “…TAG vaccine is a novel ‘triad vaccine’ that involves transfection of autologous tumor with a dual plasmid, TGFβ2 antisense gene and GM-CSF gene. Patients with…”
    Get full text
    Journal Article
  5. 5

    Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference by Rao, D D, Maples, P B, Senzer, N, Kumar, P, Wang, Z, Pappen, B O, Yu, Y, Haddock, C, Jay, C, Phadke, A P, Chen, S, Kuhn, J, Dylewski, D, Scott, S, Monsma, D, Webb, C, Tong, A, Shanahan, D, Nemunaitis, J

    Published in Cancer gene therapy (01-11-2010)
    “…RNA interference (RNAi) is a natural cellular regulatory process that inhibits gene expression by transcriptional, post-transcriptional and translational…”
    Get full text
    Journal Article
  6. 6

    Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine by Jay, C M, Ruoff, C, Kumar, P, Maass, H, Spanhel, B, Miller, M, Arrington, A, Montalvo, N, Gresham, V, Rao, D D, Evans, C, Wang, Z, Brunicardi, F C, Liu, S-H, Zhou, G, Senzer, N, Nemunaitis, J, King, L, Weeks, B, Clubb, F J, Fossum, T W, Maples, P B

    Published in Cancer gene therapy (01-12-2013)
    “…PDX1 (pancreatic and duodenal homeobox 1) is overexpressed in pancreatic cancer, and its reduction results in tumor regression. Bi-functional pbi-shRNA PDX1…”
    Get full text
    Journal Article
  7. 7

    Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow by Smith, S L, Bender, J G, Maples, P B, Unverzagt, K, Schilling, M, Lum, L, Williams, S, Van Epps, D E

    Published in Experimental hematology (01-07-1993)
    “…The growth and differentiation of selected bone marrow CD34+ cells stimulated with hematopoietic growth factors in lipid cultures were evaluated to determine…”
    Get more information
    Journal Article
  8. 8

    Differential expression of alpha- and beta-globin genes in erythroleukemic cell lines by BERU, N, MAPLES, P. B, HERMINE, O, GOLDWASSER, E

    Published in Molecular and Cellular Biology (01-07-1990)
    “…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Determination of hemoglobin expression patterns in erythroid cells of Rana catesbeiana tadpoles by Maples, P B, Palmer, J C, Broyles, R H

    “…1. Rana catesbeiana (bullfrog) tadpoles are heterogeneous in the relative amounts of four major tadpole hemoglobins (Hbs), as well as in the relative amounts…”
    Get more information
    Journal Article
  11. 11
  12. 12

    Immune response and survival of refractory cancer patients who received TGF-[beta]2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine by Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

    Published in Gene therapy (01-09-2013)
    “…TAG vaccine is a novel 'triad vaccine' that involves transfection of autologous tumor with a dual plasmid, TGF[beta]2 antisense gene and GM-CSF gene. Patients…”
    Get full text
    Journal Article
  13. 13

    In vivo regulation of hemoglobin phenotypes of developing Rana catesbeiana by Maples, Phillip B., Palmer, Janet C., Broyles, Robert H.

    Published in Developmental biology (01-10-1986)
    “…We have examined the effects of phenylhydrazine-induced anemia on the in vivo synthesis of specific hemoglobins at larval, metamorphic, and post-metamorphic…”
    Get full text
    Journal Article
  14. 14

    Phase II trial of Belagenpumatucel-L, a TGF-[beta]2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients by Nemunaitis, J, Nemunaitis, M, Senzer, N, Snitz, P, Bedell, C, Kumar, P, Pappen, B, Maples, P B, Shawler, D, Fakhrai, H

    Published in Cancer gene therapy (01-08-2009)
    “…In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response…”
    Get full text
    Journal Article
  15. 15

    Phase II trial of Belagenpumatucel-L, a TGF-b2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients by Nemunaitis, J, Nemunaitis, M, Senzer, N, Snitz, P, Bedell, C, Kumar, P, Pappen, B, Maples, P B, Shawler, D, Fakhrai, H

    Published in Cancer gene therapy (01-08-2009)
    “…In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response…”
    Get full text
    Journal Article
  16. 16

    Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients by Nemunaitis, J, Nemunaitis, M, Senzer, N, Snitz, P, Bedell, C, Kumar, P, Pappen, B, Maples, P B, Shawler, D, Fakhrai, H

    Published in Cancer gene therapy (01-08-2009)
    “…In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response…”
    Get full text
    Journal Article
  17. 17

    Embryonic and larval hemoglobins during the early development of the bullfrog, Rana catesbeiana by Maples, Phillip B., Dorn, Allan R., Broyles, Robert H.

    Published in Developmental biology (01-04-1983)
    “…The main hemoglobin (Hb) found in Shumway (embryonic) stage 25 bullfrogs is that which we have designated Td-4. The other major tadpole Hbs (Td-1, 2, and 3)…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20